


ADDENDUM TO MAY 2011 MINUTES FOR DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS

At the May 11–12, 2011, meeting, the Pharmacy and Therapeutics Committee, based on experience with the Uniform Formulary, changes in economic circumstances, and other appropriate factors, voted (14 for, 0 against, 3 abstain, 0 absent) to recommend an adjustment to the per prescription co-payments established in Title 32, Code of Federal Regulations, Section (Sec.) 199.21(i)(2). The proposed co-payment changes for tiers 1 (generic)/2 (formulary)/3 (non-formulary) are \$5/\$12/\$25 for up to a 30-day supply at the Retail Network, and \$0/\$9/\$25 for up to a 90-day supply at the Mail Order Pharmacy. These adjusted amounts maintain compliance with the requirements of Title 10, United States Code, Sec. 1074g(a)(6).


SUBMITTED BY:



John P. Kugler, M.D., MPH
Chair, Department of Defense Pharmacy
and Therapeutics Committee

DECISION ON RECOMMENDATIONS:

The recommended co-pay adjustment is approved effective October 1, 2011. For formulary and generic pharmaceutical agents obtained from a retail non-network pharmacy there is a 20 percent or \$12.00 co-payment (whichever is greater) per prescription for up to a 30-day supply. For non-formulary pharmaceutical agents obtained at a retail non-network pharmacy there is a 20 percent or \$25.00 co-payment (whichever is greater) per prescription for up to a 30-day supply.



Jonathan Woodson, M.D.
Assistant Secretary of Defense
(Health Affairs)

5 August 2011
(Date)